| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.82 | 0.15 (+3.21%) | 2.55 - 6.25 | 277.2 thousand (Above Avg) |
Market data as of 4:00PM 05/21/13. Quotes are delayed by at least 15 min.
| Open | 4.66 |
|---|---|
| Previous Close | 4.67 |
| Day's Range | 4.31 - 4.84 |
| Market Cap | 178.8M |
| Avg Volume (10 Day) | 190.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.36 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Ampio Pharmaceuticals Announces Participation at the UBS Global Healthcare Conference
PR Newswire - Monday 05/13/2013 8:00 AM ET
Ampio Pharmaceuticals Completes Enrollment in Run-In SPRING study of Ampion in Osteoarthritis of the Knee
PR Newswire - Thursday 04/25/2013 8:00 AM ET
| AMPE | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 60.00% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 3464.35 |
| Company | Last | Change |
|---|---|---|
| SIGA Technologies Inc | 3.51 | -2.50% |
| Zogenix Inc | 1.52 | -3.18% |
| Horizon Pharma Inc | 2.38 | -0.42% |
| KaloBios Pharmaceuticals Inc | 5.85 | +0.86% |
| Alimera Sciences Inc | 4.42 | +0.91% |
Data is delayed by at least 15 min.